~~<i id='6670FCDD8F'><strike id='6670FCDD8F'><tt id='6670FCDD8F'><pre id='6670FCDD8F'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：focus 2025-08-10 05:42:20 Page View：46

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What will save rural psychiatry services? Higher Medicaid payments
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Advancesingenetherapycouldeventually"cure"manyformsofcongenitaldeafness.Thechangeshavemanydeafpeople

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Greece's new parliament sworn in following conservative party's election victory

GreeklawmakerstaketheoathduringaswearinginceremonyattheparliamentinAthens,Greece,Monday,July3,2023.T